# Kenneth C. Anderson

Source: https://onco.cc/people/kenneth-anderson/  
OnCo record `kenneth-anderson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Translated bortezomib and lenalidomide from bench to bedside, helping turn myeloma from a two-year to a decade-plus disease.

## Summary

Kenneth C. Anderson is the Kraft Family Professor of Medicine and Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Brigham Cancer Center. He is a myeloma pioneer known for translating bortezomib and lenalidomide from bench to bedside, with laboratory and clinical work that underpinned their approval and that of later novel agents. His selected paper reports bortezomib versus high-dose dexamethasone for relapsed multiple myeloma. He remains long-time director of the Lipper Myeloma Center, working on proteasome inhibitors and immunomodulatory drugs.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Kraft Family Professor of Medicine; Director, Jerome Lipper Multiple Myeloma Center
- Specialisms: Multiple myeloma; Proteasome inhibitors; Immunomodulatory drugs

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Kenneth_C._Anderson_(physician)
- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/kenneth-c-anderson
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20KC%5BAuthor%5D

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)

---
JSON: https://onco.cc/api/v1/entities/kenneth-anderson.json